7298 Upper Clarenton Drive South
89 articles with Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public offering of 13,333,334 common shares (the “Offering”). The shares were sold at a public offering price of US$15.00 per share. The gross offering pro
Aurinia Pharmaceuticals Inc. announced the pricing of its underwritten public offering of 13,333,334 common shares.
Aurinia Pharmaceuticals Inc., a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced that it has commenced a registered underwritten public offering of its common shares.
Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for voclosporin,
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Voclosporin ophthalmic solution (VOS) results anticipated in the fourth quarter of 2020
Aurinia Pharmaceuticals Inc. announced that additional safety data from the completed AURORA pivotal trial of voclosporin were shared at the European Renal Association-European Dialysis and Transplant Association 2020 Virtual Congress in an oral presentation given by nephrologist Dawn Caster, M.D., Assistant Professor of Medicine at the University of Louisville School of Medicine.
All pre-specified subgroup analyses in the pivotal trial favored voclosporin over placebo
Aurinia Pharmaceuticals Inc. is pleased to announce that the nine incumbent directors of the Company were elected at the Company’s annual general meeting held on June 2, 2020.
Aurinia Pharmaceuticals Inc. announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during the 2020 Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 3:30 p.m. EDT.